{"transactions":[{"id":306910,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2026-07-23T20:15:41.000Z","date":"2026-07-21","kind":"grant","planned":false,"acquired":true,"shares":8251,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted stock unit award that vests on 03/31/2030."}],"balance_after":53572,"source":{"system":"sec-edgar","filing":"0000875320-26-000253","document":"wk-form4_1784837739.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000087532026000253/wk-form4_1784837739.xml","form_type":"4"}},{"id":307413,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2026-07-07T20:15:41.000Z","date":"2026-07-02","kind":"sale","planned":true,"acquired":false,"shares":1500,"price":524.99,"value":787485.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Tatsis' company approved trading plan under Rule 10b5-1, which was entered into on 08/21/2025."}],"balance_after":45321,"source":{"system":"sec-edgar","filing":"0000875320-26-000245","document":"wk-form4_1783455338.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000087532026000245/wk-form4_1783455338.xml","form_type":"4"}},{"id":785817,"issuer":{"id":4850,"kind":"organization","name":"Odyssey Therapeutics, Inc."},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-12T00:30:11.000Z","date":"2026-05-07","kind":"grant","planned":false,"acquired":true,"shares":27393,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option will vest in full on May 7, 2027, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":27393,"derivative":{"exercise_price":18,"expiration_date":"2036-05-06","underlying":"Common Stock","underlying_shares":27393},"source":{"system":"sec-edgar","filing":"0001193125-26-217588","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000119312526217588/ownership.xml","form_type":"4"}},{"id":312724,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2026-02-26T23:55:12.000Z","date":"2026-02-25","kind":"sale","planned":true,"acquired":false,"shares":260,"price":486.35,"value":126451.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Tatsis' company approved trading plan under Rule 10b5-1, which was entered into on 08/21/2025."}],"balance_after":46763,"source":{"system":"sec-edgar","filing":"0000875320-26-000120","document":"wk-form4_1772150109.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000087532026000120/wk-form4_1772150109.xml","form_type":"4"}},{"id":312723,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2026-02-26T23:55:12.000Z","date":"2026-02-24","kind":"tax_withholding","planned":true,"acquired":false,"shares":1627,"price":485.11,"value":789273.97,"ownership":{"direct":true},"balance_after":47023,"source":{"system":"sec-edgar","filing":"0000875320-26-000120","document":"wk-form4_1772150109.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000087532026000120/wk-form4_1772150109.xml","form_type":"4"}},{"id":313131,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2026-02-19T21:28:26.000Z","date":"2026-02-18","kind":"sale","planned":true,"acquired":false,"shares":368,"price":473.68,"value":174314.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Transaction made pursuant to Dr. Tatsis' company approved trading plan under Rule 10b5-1, which was entered into on 08/21/2025."}],"balance_after":48650,"source":{"system":"sec-edgar","filing":"0000875320-26-000098","document":"wk-form4_1771536504.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000087532026000098/wk-form4_1771536504.xml","form_type":"4"}},{"id":313130,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2026-02-19T21:28:26.000Z","date":"2026-02-17","kind":"sale","planned":true,"acquired":false,"shares":609,"price":489.46,"value":298081.14,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Transaction made pursuant to Dr. Tatsis' company approved trading plan under Rule 10b5-1, which was entered into on 08/21/2025."}],"balance_after":49018,"source":{"system":"sec-edgar","filing":"0000875320-26-000098","document":"wk-form4_1771536504.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000087532026000098/wk-form4_1771536504.xml","form_type":"4"}},{"id":313129,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2026-02-19T21:28:26.000Z","date":"2026-02-17","kind":"tax_withholding","planned":true,"acquired":false,"shares":2294,"price":483.75,"value":1109722.5,"ownership":{"direct":true},"balance_after":49627,"source":{"system":"sec-edgar","filing":"0000875320-26-000098","document":"wk-form4_1771536504.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000087532026000098/wk-form4_1771536504.xml","form_type":"4"}},{"id":313128,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2026-02-19T21:28:26.000Z","date":"2026-02-17","kind":"grant","planned":true,"acquired":true,"shares":5789,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted stock unit award that vests in installments beginning on February 20, 2027."}],"balance_after":51921,"source":{"system":"sec-edgar","filing":"0000875320-26-000098","document":"wk-form4_1771536504.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000087532026000098/wk-form4_1771536504.xml","form_type":"4"}},{"id":313472,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2026-02-18T21:43:59.000Z","date":"2026-02-13","kind":"sale","planned":true,"acquired":false,"shares":1500,"price":499.99,"value":749985.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Tatsis' company approved trading plan under Rule 10b5-1, which was entered into on 08/21/2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Open market sales reported on this line occurred at a weighted average price of $499.99 (range $499.99 to $500.04)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Dr. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."}],"balance_after":46132,"source":{"system":"sec-edgar","filing":"0000875320-26-000076","document":"wk-form4_1771451036.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000087532026000076/wk-form4_1771451036.xml","form_type":"4"}},{"id":313471,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2026-02-18T21:43:59.000Z","date":"2026-02-13","kind":"tax_withholding","planned":true,"acquired":false,"shares":3804,"price":487.76,"value":1855439.04,"ownership":{"direct":true},"balance_after":47632,"source":{"system":"sec-edgar","filing":"0000875320-26-000076","document":"wk-form4_1771451036.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000087532026000076/wk-form4_1771451036.xml","form_type":"4"}},{"id":313859,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2026-02-12T22:08:53.000Z","date":"2026-02-11","kind":"sale","planned":true,"acquired":false,"shares":466,"price":460.43,"value":214560.38,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Tatsis' company approved trading plan under Rule 10b5-1, which was entered into on 08/21/2025."}],"balance_after":51436,"source":{"system":"sec-edgar","filing":"0000875320-26-000052","document":"wk-form4_1770934130.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000087532026000052/wk-form4_1770934130.xml","form_type":"4"}},{"id":313858,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2026-02-12T22:08:53.000Z","date":"2026-02-10","kind":"tax_withholding","planned":true,"acquired":false,"shares":2140,"price":468.41,"value":1002397.4,"ownership":{"direct":true},"balance_after":51902,"source":{"system":"sec-edgar","filing":"0000875320-26-000052","document":"wk-form4_1770934130.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000087532026000052/wk-form4_1770934130.xml","form_type":"4"}},{"id":314825,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2026-01-26T21:37:15.000Z","date":"2026-01-22","kind":"grant","planned":false,"acquired":true,"shares":3883,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents earned performance shares with respect to a performance stock unit award granted on 02/12/2025 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest in installments beginning on 02/24/2026."}],"balance_after":54042,"source":{"system":"sec-edgar","filing":"0000875320-26-000026","document":"wk-form4_1769463422.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000087532026000026/wk-form4_1769463422.xml","form_type":"4"}},{"id":314824,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2026-01-26T21:37:15.000Z","date":"2026-01-22","kind":"grant","planned":false,"acquired":true,"shares":7866,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2023 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest on 02/13/2026."}],"balance_after":50159,"source":{"system":"sec-edgar","filing":"0000875320-26-000026","document":"wk-form4_1769463422.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000087532026000026/wk-form4_1769463422.xml","form_type":"4"}},{"id":315352,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2026-01-09T21:05:25.000Z","date":"2026-01-07","kind":"sale","planned":true,"acquired":false,"shares":4500,"price":474.99,"value":2137455.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Tatsis' company approved trading plan under Rule 10b5-1, which was entered into on 08/21/2025."}],"balance_after":42293,"source":{"system":"sec-edgar","filing":"0000875320-26-000004","document":"wk-form4_1767992722.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000087532026000004/wk-form4_1767992722.xml","form_type":"4"}},{"id":316509,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2025-12-05T21:12:54.000Z","date":"2025-12-03","kind":"sale","planned":true,"acquired":false,"shares":4500,"price":449.99,"value":2024955.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Tatsis' company approved trading plan under Rule 10b5-1, which was entered into on 08/21/2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Open market sales reported on this line occurred at a weighted average price of $449.99 (range $449.99 to $450.00)."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Dr. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."}],"balance_after":46793,"source":{"system":"sec-edgar","filing":"0000875320-25-000244","document":"wk-form4_1764969166.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000087532025000244/wk-form4_1764969166.xml","form_type":"4"}},{"id":1081058,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-07-28T21:15:08.000Z","date":"2025-07-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":42200,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of an Agreement and Plan of Merger, dated as of June 16, 2025, by and among the Issuer, Eli Lilly and Company (\"Parent\") and Parent's indirect wholly owned subsidiary, Ridgeway Acquisition Corporation, at the effective time of the Merger (the \"Effective Time\"), each outstanding stock option of Issuer having an exercise price less than $10.50 per share in cash, without interest and less any applicable tax withholding (the \"Cash Consideration\") (each such option, a \"Cash-Out Stock Option\") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from footnote 1) applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one non-tradeable contingent value right for each share subject to such Cash-Out Stock Option (without regard to vesting)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of an Agreement and Plan of Merger, dated as of June 16, 2025, by and among the Issuer, Eli Lilly and Company (\"Parent\") and Parent's indirect wholly owned subsidiary, Ridgeway Acquisition Corporation, at the effective time of the Merger (the \"Effective Time\"), each outstanding stock option of Issuer having an exercise price less than $10.50 per share in cash, without interest and less any applicable tax withholding (the \"Cash Consideration\") (each such option, a \"Cash-Out Stock Option\") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(continued from footnote 1) applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one non-tradeable contingent value right for each share subject to such Cash-Out Stock Option (without regard to vesting)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to the terms of an Agreement and Plan of Merger, dated as of June 16, 2025, by and among the Issuer, Eli Lilly and Company (\"Parent\") and Parent's indirect wholly owned subsidiary, Ridgeway Acquisition Corporation, at the effective time of the Merger (the \"Effective Time\"), each outstanding stock option of Issuer having an exercise price less than $10.50 per share in cash, without interest and less any applicable tax withholding (the \"Cash Consideration\") (each such option, a \"Cash-Out Stock Option\") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"(continued from footnote 1) applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one non-tradeable contingent value right for each share subject to such Cash-Out Stock Option (without regard to vesting)."}],"balance_after":0,"derivative":{"exercise_price":5.73,"underlying":"Common Stock","underlying_shares":42200},"source":{"system":"sec-edgar","filing":"0000950170-25-099252","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000095017025099252/ownership.xml","form_type":"4"}},{"id":1081057,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-07-28T21:15:08.000Z","date":"2025-07-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":267541,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of an Agreement and Plan of Merger, dated as of June 16, 2025, by and among the Issuer, Eli Lilly and Company (\"Parent\") and Parent's indirect wholly owned subsidiary, Ridgeway Acquisition Corporation, at the effective time of the Merger (the \"Effective Time\"), each outstanding stock option of Issuer having an exercise price less than $10.50 per share in cash, without interest and less any applicable tax withholding (the \"Cash Consideration\") (each such option, a \"Cash-Out Stock Option\") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from footnote 1) applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one non-tradeable contingent value right for each share subject to such Cash-Out Stock Option (without regard to vesting)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of an Agreement and Plan of Merger, dated as of June 16, 2025, by and among the Issuer, Eli Lilly and Company (\"Parent\") and Parent's indirect wholly owned subsidiary, Ridgeway Acquisition Corporation, at the effective time of the Merger (the \"Effective Time\"), each outstanding stock option of Issuer having an exercise price less than $10.50 per share in cash, without interest and less any applicable tax withholding (the \"Cash Consideration\") (each such option, a \"Cash-Out Stock Option\") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(continued from footnote 1) applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one non-tradeable contingent value right for each share subject to such Cash-Out Stock Option (without regard to vesting)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to the terms of an Agreement and Plan of Merger, dated as of June 16, 2025, by and among the Issuer, Eli Lilly and Company (\"Parent\") and Parent's indirect wholly owned subsidiary, Ridgeway Acquisition Corporation, at the effective time of the Merger (the \"Effective Time\"), each outstanding stock option of Issuer having an exercise price less than $10.50 per share in cash, without interest and less any applicable tax withholding (the \"Cash Consideration\") (each such option, a \"Cash-Out Stock Option\") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"(continued from footnote 1) applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one non-tradeable contingent value right for each share subject to such Cash-Out Stock Option (without regard to vesting)."}],"balance_after":0,"derivative":{"exercise_price":5.02,"underlying":"Common Stock","underlying_shares":267541},"source":{"system":"sec-edgar","filing":"0000950170-25-099252","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000095017025099252/ownership.xml","form_type":"4"}},{"id":1120520,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-06T21:00:22.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":42200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option was issued pursuant to the 2021 Stock Incentive Plan of Verve Therapeutics, Inc. in accordance with its director compensation program. The vesting commencement date (the \"Vesting Commencement Date\") of the options is the grant date. All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or immediately prior to the first annual meeting of stockholders occurring after the grant date, in each case subject to the Reporting Person's continued service as a director."}],"balance_after":42200,"derivative":{"exercise_price":5.73,"expiration_date":"2035-06-04","underlying":"Common Stock","underlying_shares":42200},"source":{"system":"sec-edgar","filing":"0000950170-25-083227","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000095017025083227/ownership.xml","form_type":"4"}},{"id":324119,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2025-03-12T20:10:34.000Z","date":"2025-03-10","kind":"sale","planned":true,"acquired":false,"shares":3242,"price":499.99,"value":1620967.58,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Tatsis' company approved trading plan under Rule 10b5-1, which was entered into on 11/22/2024."}],"balance_after":51239,"source":{"system":"sec-edgar","filing":"0000875320-25-000146","document":"wk-form4_1741810227.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000087532025000146/wk-form4_1741810227.xml","form_type":"4"}},{"id":324502,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2025-03-06T21:08:52.000Z","date":"2025-03-04","kind":"sale","planned":true,"acquired":false,"shares":4058,"price":485.49,"value":1970118.42,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Tatsis' company approved trading plan under Rule 10b5-1, which was entered into on 11/22/2024."}],"balance_after":54481,"source":{"system":"sec-edgar","filing":"0000875320-25-000141","document":"wk-form4_1741295323.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000087532025000141/wk-form4_1741295323.xml","form_type":"4"}},{"id":325019,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2025-02-28T21:48:38.000Z","date":"2025-02-27","kind":"sale","planned":true,"acquired":false,"shares":530,"price":475.34,"value":251930.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Tatsis' company approved trading plan under Rule 10b5-1, which was entered into on 02/29/2024."}],"balance_after":58539,"source":{"system":"sec-edgar","filing":"0000875320-25-000135","document":"wk-form4_1740779311.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000087532025000135/wk-form4_1740779311.xml","form_type":"4"}},{"id":325018,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2025-02-28T21:48:38.000Z","date":"2025-02-26","kind":"tax_withholding","planned":true,"acquired":false,"shares":4962,"price":479.61,"value":2379824.82,"ownership":{"direct":true},"balance_after":59069,"source":{"system":"sec-edgar","filing":"0000875320-25-000135","document":"wk-form4_1740779311.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000087532025000135/wk-form4_1740779311.xml","form_type":"4"}},{"id":325175,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2025-02-26T21:15:07.000Z","date":"2025-02-25","kind":"sale","planned":true,"acquired":false,"shares":354,"price":480.95,"value":170256.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Tatsis' company approved trading plan under Rule 10b5-1, which was entered into on 02/29/2024."}],"balance_after":64031,"source":{"system":"sec-edgar","filing":"0000875320-25-000115","document":"wk-form4_1740604500.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000087532025000115/wk-form4_1740604500.xml","form_type":"4"}},{"id":325174,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2025-02-26T21:15:07.000Z","date":"2025-02-24","kind":"tax_withholding","planned":true,"acquired":false,"shares":3310,"price":483.28,"value":1599656.8,"ownership":{"direct":true},"balance_after":64385,"source":{"system":"sec-edgar","filing":"0000875320-25-000115","document":"wk-form4_1740604500.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000087532025000115/wk-form4_1740604500.xml","form_type":"4"}},{"id":325780,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2025-02-19T21:36:42.000Z","date":"2025-02-18","kind":"sale","planned":true,"acquired":false,"shares":244,"price":455.06,"value":111034.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1, which was entered into on 02/29/2024."}],"balance_after":67695,"source":{"system":"sec-edgar","filing":"0000875320-25-000095","document":"wk-form4_1740000996.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000087532025000095/wk-form4_1740000996.xml","form_type":"4"}},{"id":325779,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2025-02-19T21:36:42.000Z","date":"2025-02-14","kind":"tax_withholding","planned":true,"acquired":false,"shares":2293,"price":463.46,"value":1062713.78,"ownership":{"direct":true},"balance_after":67939,"source":{"system":"sec-edgar","filing":"0000875320-25-000095","document":"wk-form4_1740000996.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000087532025000095/wk-form4_1740000996.xml","form_type":"4"}},{"id":326064,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2025-02-14T21:18:59.000Z","date":"2025-02-12","kind":"grant","planned":false,"acquired":true,"shares":6211,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted stock unit award that vests in installments beginning on 02/24/2026."}],"balance_after":70232,"source":{"system":"sec-edgar","filing":"0000875320-25-000073","document":"wk-form4_1739567930.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000087532025000073/wk-form4_1739567930.xml","form_type":"4"}},{"id":326167,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2025-02-12T21:50:37.000Z","date":"2025-02-11","kind":"sale","planned":true,"acquired":false,"shares":310,"price":459.83,"value":142547.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1, which was entered into on 02/29/2024."}],"balance_after":64021,"source":{"system":"sec-edgar","filing":"0000875320-25-000048","document":"wk-form4_1739397030.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000087532025000048/wk-form4_1739397030.xml","form_type":"4"}},{"id":326166,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2025-02-12T21:50:37.000Z","date":"2025-02-10","kind":"tax_withholding","planned":true,"acquired":false,"shares":2143,"price":467.98,"value":1002881.14,"ownership":{"direct":true},"balance_after":64331,"source":{"system":"sec-edgar","filing":"0000875320-25-000048","document":"wk-form4_1739397030.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000087532025000048/wk-form4_1739397030.xml","form_type":"4"}},{"id":326547,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2025-02-06T21:43:41.000Z","date":"2025-02-04","kind":"grant","planned":false,"acquired":true,"shares":7114,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents earned performance shares with respect to a performance stock unit award granted on 02/07/2024 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/04/2025 and the shares will vest in installments beginning on 02/17/2025."}],"balance_after":66474,"source":{"system":"sec-edgar","filing":"0000875320-25-000024","document":"wk-form4_1738878214.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000087532025000024/wk-form4_1738878214.xml","form_type":"4"}},{"id":326546,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2025-02-06T21:43:41.000Z","date":"2025-02-04","kind":"grant","planned":false,"acquired":true,"shares":10262,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2022 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/04/2025 and the shares will vest on 02/26/2025."}],"balance_after":59360,"source":{"system":"sec-edgar","filing":"0000875320-25-000024","document":"wk-form4_1738878214.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000087532025000024/wk-form4_1738878214.xml","form_type":"4"}},{"id":1467722,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-28T11:45:08.000Z","date":"2024-06-26","kind":"grant","planned":false,"acquired":true,"shares":267541,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option was issued pursuant to the 2021 Stock Incentive Plan of Verve Therapeutics, Inc. in accordance with its director compensation program. The vesting commencement date of the option is the grant date. The shares of common stock underlying the option are scheduled to vest in equal monthly installments through June 26, 2027, subject to the Reporting Person's continued service as a director."}],"balance_after":267541,"derivative":{"exercise_price":5.02,"expiration_date":"2034-06-25","underlying":"Common Stock","underlying_shares":267541},"source":{"system":"sec-edgar","filing":"0000950170-24-078782","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000095017024078782/ownership.xml","form_type":"4"}},{"id":333064,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2024-06-05T20:08:55.000Z","date":"2024-06-03","kind":"sale","planned":true,"acquired":false,"shares":2175,"price":460,"value":1000500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1, which was entered into on 02/29/2024."}],"balance_after":49098,"source":{"system":"sec-edgar","filing":"0000875320-24-000168","document":"wk-form4_1717618128.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000087532024000168/wk-form4_1717618128.xml","form_type":"4"}},{"id":333152,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2024-06-03T20:09:13.000Z","date":"2024-05-31","kind":"sale","planned":true,"acquired":false,"shares":2250,"price":445,"value":1001250.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1, which was entered into on 02/29/2024."}],"balance_after":51273,"source":{"system":"sec-edgar","filing":"0000875320-24-000166","document":"wk-form4_1717445345.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000087532024000166/wk-form4_1717445345.xml","form_type":"4"}},{"id":333151,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2024-06-03T20:09:13.000Z","date":"2024-05-30","kind":"sale","planned":true,"acquired":false,"shares":2350,"price":439.11,"value":1031908.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1, which was entered into on 02/29/2024."}],"balance_after":53523,"source":{"system":"sec-edgar","filing":"0000875320-24-000166","document":"wk-form4_1717445345.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000087532024000166/wk-form4_1717445345.xml","form_type":"4"}},{"id":339119,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2024-02-27T22:02:56.000Z","date":"2024-02-26","kind":"sale","planned":true,"acquired":false,"shares":354,"price":425.7,"value":150697.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1, which was entered into on 05/09/2023."}],"balance_after":55804,"source":{"system":"sec-edgar","filing":"0000875320-24-000109","document":"wk-form4_1709071355.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000087532024000109/wk-form4_1709071355.xml","form_type":"4"}},{"id":339118,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2024-02-27T22:02:56.000Z","date":"2024-02-23","kind":"tax_withholding","planned":true,"acquired":false,"shares":3309,"price":431.79,"value":1428793.11,"ownership":{"direct":true},"balance_after":56158,"source":{"system":"sec-edgar","filing":"0000875320-24-000109","document":"wk-form4_1709071355.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000087532024000109/wk-form4_1709071355.xml","form_type":"4"}},{"id":339398,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2024-02-23T21:28:11.000Z","date":"2024-02-21","kind":"sale","planned":true,"acquired":false,"shares":360,"price":421.77,"value":151837.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1, which was entered into on 05/09/2023."}],"balance_after":59467,"source":{"system":"sec-edgar","filing":"0000875320-24-000093","document":"wk-form4_1708723675.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000087532024000093/wk-form4_1708723675.xml","form_type":"4"}},{"id":339685,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2024-02-21T21:43:13.000Z","date":"2024-02-20","kind":"sale","planned":true,"acquired":false,"shares":480,"price":420.79,"value":201979.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1, which was entered into on 05/09/2023."}],"balance_after":59827,"source":{"system":"sec-edgar","filing":"0000875320-24-000080","document":"wk-form4_1708551763.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000087532024000080/wk-form4_1708551763.xml","form_type":"4"}},{"id":339684,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2024-02-21T21:43:13.000Z","date":"2024-02-20","kind":"tax_withholding","planned":true,"acquired":false,"shares":3373,"price":420.58,"value":1418616.34,"ownership":{"direct":true},"balance_after":60307,"source":{"system":"sec-edgar","filing":"0000875320-24-000080","document":"wk-form4_1708551763.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000087532024000080/wk-form4_1708551763.xml","form_type":"4"}},{"id":339683,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2024-02-21T21:43:13.000Z","date":"2024-02-16","kind":"tax_withholding","planned":true,"acquired":false,"shares":4499,"price":424.01,"value":1907620.99,"ownership":{"direct":true},"balance_after":63680,"source":{"system":"sec-edgar","filing":"0000875320-24-000080","document":"wk-form4_1708551763.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000087532024000080/wk-form4_1708551763.xml","form_type":"4"}},{"id":340492,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2024-02-13T22:23:36.000Z","date":"2024-02-12","kind":"sale","planned":true,"acquired":false,"shares":314,"price":420.24,"value":131955.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1, which was entered into on 05/09/2023."}],"balance_after":68179,"source":{"system":"sec-edgar","filing":"0000875320-24-000055","document":"wk-form4_1707862996.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000087532024000055/wk-form4_1707862996.xml","form_type":"4"}},{"id":340491,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2024-02-13T22:23:36.000Z","date":"2024-02-09","kind":"tax_withholding","planned":true,"acquired":false,"shares":2100,"price":422.74,"value":887754.0,"ownership":{"direct":true},"balance_after":68493,"source":{"system":"sec-edgar","filing":"0000875320-24-000055","document":"wk-form4_1707862996.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000087532024000055/wk-form4_1707862996.xml","form_type":"4"}},{"id":341065,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2024-02-08T21:45:38.000Z","date":"2024-02-07","kind":"grant","planned":false,"acquired":true,"shares":7114,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Restricted stock unit award that vests in installments beginning on 02/17/2025."}],"balance_after":70593,"source":{"system":"sec-edgar","filing":"0000875320-24-000032","document":"wk-form4_1707428720.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000087532024000032/wk-form4_1707428720.xml","form_type":"4"}},{"id":341064,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2024-02-08T21:45:38.000Z","date":"2024-02-06","kind":"grant","planned":false,"acquired":true,"shares":7866,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2023 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on  02/06/2024 and the shares will vest in installments beginning on 02/10/2024."}],"balance_after":63479,"source":{"system":"sec-edgar","filing":"0000875320-24-000032","document":"wk-form4_1707428720.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000087532024000032/wk-form4_1707428720.xml","form_type":"4"}},{"id":341063,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2024-02-08T21:45:38.000Z","date":"2024-02-06","kind":"grant","planned":false,"acquired":true,"shares":6976,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents earned performance shares with respect to a performance stock unit award granted on 02/03/2021 that contained performance-vesting requirements. The issuer's management development and compensation\ncommittee certified as to the level of performance-goal attainment on 02/06/2024 and the shares will vest on 02/20/2024."}],"balance_after":55613,"source":{"system":"sec-edgar","filing":"0000875320-24-000032","document":"wk-form4_1707428720.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000087532024000032/wk-form4_1707428720.xml","form_type":"4"}},{"id":346194,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2023-08-25T20:14:50.000Z","date":"2023-08-23","kind":"sale","planned":true,"acquired":false,"shares":2500,"price":355,"value":887500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1, which was entered into on 05/09/2023."}],"balance_after":48637,"source":{"system":"sec-edgar","filing":"0001209191-23-047309","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000120919123047309/doc4.xml","form_type":"4"}},{"id":346634,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2023-08-14T20:08:52.000Z","date":"2023-08-10","kind":"sale","planned":true,"acquired":false,"shares":5750,"price":345.79,"value":1988292.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1, which was entered into on 05/09/2023."}],"balance_after":51137,"source":{"system":"sec-edgar","filing":"0000899243-23-018112","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000089924323018112/doc4.xml","form_type":"4"}},{"id":352325,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2023-02-28T22:11:24.000Z","date":"2023-02-27","kind":"sale","acquired":false,"shares":20,"price":289.29,"value":5785.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Open market sales reported on this line occurred at a weighted average price of $289.29 (range $289.17 to $289.40)."}],"balance_after":56805,"source":{"system":"sec-edgar","filing":"0001209191-23-013765","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000120919123013765/doc4.xml","form_type":"4"}},{"id":352324,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2023-02-28T22:11:24.000Z","date":"2023-02-27","kind":"sale","acquired":false,"shares":51,"price":288.33,"value":14704.83,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Open market sales reported on this line occurred at a weighted average price of $288.33 (range $287.82 to $288.74)."}],"balance_after":56825,"source":{"system":"sec-edgar","filing":"0001209191-23-013765","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000120919123013765/doc4.xml","form_type":"4"}},{"id":352323,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2023-02-28T22:11:24.000Z","date":"2023-02-27","kind":"sale","acquired":false,"shares":283,"price":287.2,"value":81277.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Open market sales reported on this line occurred at a weighted average price of $287.20 (range $286.71 to $287.60)."}],"balance_after":56876,"source":{"system":"sec-edgar","filing":"0001209191-23-013765","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000120919123013765/doc4.xml","form_type":"4"}},{"id":352322,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2023-02-28T22:11:24.000Z","date":"2023-02-24","kind":"tax_withholding","acquired":false,"shares":3308,"price":289.12,"value":956408.96,"ownership":{"direct":true},"balance_after":57159,"source":{"system":"sec-edgar","filing":"0001209191-23-013765","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000120919123013765/doc4.xml","form_type":"4"}},{"id":352888,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2023-02-22T21:48:42.000Z","date":"2023-02-21","kind":"sale","acquired":false,"shares":124,"price":294.77,"value":36551.48,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Open market sales reported on this line occurred at a weighted average price of $294.77 (range $294.42 to $295.37)."}],"balance_after":60467,"source":{"system":"sec-edgar","filing":"0001209191-23-011704","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000120919123011704/doc4.xml","form_type":"4"}},{"id":352887,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2023-02-22T21:48:42.000Z","date":"2023-02-21","kind":"sale","acquired":false,"shares":207,"price":293.83,"value":60822.81,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Open market sales reported on this line occurred at a weighted average price of $293.83 (range $293.39 to $294.38)."}],"balance_after":60591,"source":{"system":"sec-edgar","filing":"0001209191-23-011704","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000120919123011704/doc4.xml","form_type":"4"}},{"id":352886,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2023-02-22T21:48:42.000Z","date":"2023-02-21","kind":"sale","acquired":false,"shares":145,"price":292.85,"value":42463.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Open market sales reported on this line occurred at a weighted average price of $292.85 (range $292.37 to $293.36)."}],"balance_after":60798,"source":{"system":"sec-edgar","filing":"0001209191-23-011704","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000120919123011704/doc4.xml","form_type":"4"}},{"id":352885,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2023-02-22T21:48:42.000Z","date":"2023-02-21","kind":"sale","acquired":false,"shares":4,"price":291.01,"value":1164.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1."}],"balance_after":60943,"source":{"system":"sec-edgar","filing":"0001209191-23-011704","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000120919123011704/doc4.xml","form_type":"4"}},{"id":352884,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2023-02-22T21:48:42.000Z","date":"2023-02-17","kind":"tax_withholding","acquired":false,"shares":4498,"price":292.85,"value":1317239.3,"ownership":{"direct":true},"balance_after":60947,"source":{"system":"sec-edgar","filing":"0001209191-23-011704","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000120919123011704/doc4.xml","form_type":"4"}},{"id":353264,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2023-02-16T21:18:26.000Z","date":"2023-02-14","kind":"sale","acquired":false,"shares":51,"price":300.58,"value":15329.58,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Open market sales reported on this line occurred at a weighted average price of $300.58 (range $300.34 to $301.01)."}],"balance_after":65445,"source":{"system":"sec-edgar","filing":"0001209191-23-010061","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000120919123010061/doc4.xml","form_type":"4"}},{"id":353263,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2023-02-16T21:18:26.000Z","date":"2023-02-14","kind":"sale","acquired":false,"shares":135,"price":299.6,"value":40446.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Open market sales reported on this line occurred at a weighted average price of $299.60 (range $299.19 to $300.16)."}],"balance_after":65496,"source":{"system":"sec-edgar","filing":"0001209191-23-010061","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000120919123010061/doc4.xml","form_type":"4"}},{"id":353262,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2023-02-16T21:18:26.000Z","date":"2023-02-14","kind":"sale","acquired":false,"shares":43,"price":297.98,"value":12813.14,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Open market sales reported on this line occurred at a weighted average price of $297.98 (range $297.50 to $298.48)."}],"balance_after":65631,"source":{"system":"sec-edgar","filing":"0001209191-23-010061","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000120919123010061/doc4.xml","form_type":"4"}},{"id":353261,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2023-02-16T21:18:26.000Z","date":"2023-02-14","kind":"sale","acquired":false,"shares":20,"price":296.48,"value":5929.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1."}],"balance_after":65674,"source":{"system":"sec-edgar","filing":"0001209191-23-010061","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000120919123010061/doc4.xml","form_type":"4"}},{"id":353260,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2023-02-16T21:18:26.000Z","date":"2023-02-14","kind":"sale","acquired":false,"shares":71,"price":295.89,"value":21008.19,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Open market sales reported on this line occurred at a weighted average price of $295.89 (range $295.36 to $296.32)."}],"balance_after":65694,"source":{"system":"sec-edgar","filing":"0001209191-23-010061","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000120919123010061/doc4.xml","form_type":"4"}},{"id":353522,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2023-02-14T22:12:20.000Z","date":"2023-02-13","kind":"sale","acquired":false,"shares":11,"price":300.79,"value":3308.69,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1."}],"balance_after":65765,"source":{"system":"sec-edgar","filing":"0001209191-23-009237","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000120919123009237/doc4.xml","form_type":"4"}},{"id":353521,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2023-02-14T22:12:20.000Z","date":"2023-02-13","kind":"sale","acquired":false,"shares":64,"price":299.88,"value":19192.32,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Open market sales reported on this line occurred at a weighted average price of $299.88 (range $299.62 to $300.53)."}],"balance_after":65776,"source":{"system":"sec-edgar","filing":"0001209191-23-009237","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000120919123009237/doc4.xml","form_type":"4"}},{"id":353520,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2023-02-14T22:12:20.000Z","date":"2023-02-13","kind":"sale","acquired":false,"shares":120,"price":298.98,"value":35877.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Open market sales reported on this line occurred at a weighted average price of $298.98 (range $298.53 to $299.50)."}],"balance_after":65840,"source":{"system":"sec-edgar","filing":"0001209191-23-009237","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000120919123009237/doc4.xml","form_type":"4"}},{"id":353519,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2023-02-14T22:12:20.000Z","date":"2023-02-13","kind":"sale","acquired":false,"shares":78,"price":298.11,"value":23252.58,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Open market sales reported on this line occurred at a weighted average price of $298.11 (range $297.51 to $298.50)."}],"balance_after":65960,"source":{"system":"sec-edgar","filing":"0001209191-23-009237","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000120919123009237/doc4.xml","form_type":"4"}},{"id":353518,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2023-02-14T22:12:20.000Z","date":"2023-02-13","kind":"sale","acquired":false,"shares":2,"price":295.84,"value":591.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1."}],"balance_after":66038,"source":{"system":"sec-edgar","filing":"0001209191-23-009237","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000120919123009237/doc4.xml","form_type":"4"}},{"id":353517,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2023-02-14T22:12:20.000Z","date":"2023-02-13","kind":"tax_withholding","acquired":false,"shares":2995,"price":298.26,"value":893288.7,"ownership":{"direct":true},"balance_after":66040,"source":{"system":"sec-edgar","filing":"0001209191-23-009237","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000120919123009237/doc4.xml","form_type":"4"}},{"id":353516,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2023-02-14T22:12:20.000Z","date":"2023-02-10","kind":"tax_withholding","acquired":false,"shares":1377,"price":294.33,"value":405292.41,"ownership":{"direct":true},"balance_after":69035,"source":{"system":"sec-edgar","filing":"0001209191-23-009237","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000120919123009237/doc4.xml","form_type":"4"}},{"id":354141,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2023-02-03T22:01:09.000Z","date":"2023-02-01","kind":"grant","acquired":true,"shares":7866,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Restricted stock unit award that vests in installments beginning on 02/10/2024."}],"balance_after":70412,"source":{"system":"sec-edgar","filing":"0001209191-23-006996","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000120919123006996/doc4.xml","form_type":"4"}},{"id":354140,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2023-02-03T22:01:09.000Z","date":"2023-02-01","kind":"grant","acquired":true,"shares":10262,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2022 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2023 and the shares will vest in installments beginning on 02/24/2023."}],"balance_after":62546,"source":{"system":"sec-edgar","filing":"0001209191-23-006996","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000120919123006996/doc4.xml","form_type":"4"}},{"id":354139,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2023-02-03T22:01:09.000Z","date":"2023-02-01","kind":"grant","acquired":true,"shares":6194,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents earned performance shares with respect to a performance stock unit award granted on 02/05/2020 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2023 and the shares will vest on 02/13/2023."}],"balance_after":52284,"source":{"system":"sec-edgar","filing":"0001209191-23-006996","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000120919123006996/doc4.xml","form_type":"4"}},{"id":358934,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2022-08-10T20:06:08.000Z","date":"2022-08-09","kind":"sale","acquired":false,"shares":74,"price":301.67,"value":22323.58,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1."}],"balance_after":46090,"source":{"system":"sec-edgar","filing":"0000899243-22-028248","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000089924322028248/doc4.xml","form_type":"4"}},{"id":358933,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2022-08-10T20:06:08.000Z","date":"2022-08-09","kind":"sale","acquired":false,"shares":72,"price":300.64,"value":21646.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1."}],"balance_after":46164,"source":{"system":"sec-edgar","filing":"0000899243-22-028248","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000089924322028248/doc4.xml","form_type":"4"}},{"id":358932,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2022-08-10T20:06:08.000Z","date":"2022-08-09","kind":"sale","acquired":false,"shares":283,"price":299.79,"value":84840.57,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Open market sales reported on this line occurred at a weighted average price of $299.79 (range $299.44 to $300.33)."}],"balance_after":46236,"source":{"system":"sec-edgar","filing":"0000899243-22-028248","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000089924322028248/doc4.xml","form_type":"4"}},{"id":358931,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2022-08-10T20:06:08.000Z","date":"2022-08-09","kind":"sale","acquired":false,"shares":679,"price":298.77,"value":202864.83,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Open market sales reported on this line occurred at a weighted average price of $298.77 (range $298.29 to $299.19)."}],"balance_after":46519,"source":{"system":"sec-edgar","filing":"0000899243-22-028248","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000089924322028248/doc4.xml","form_type":"4"}},{"id":358930,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2022-08-10T20:06:08.000Z","date":"2022-08-09","kind":"sale","acquired":false,"shares":292,"price":297.54,"value":86881.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Open market sales reported on this line occurred at a weighted average price of $297.54 (range $297.00 to $297.80)."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 134 shares previously purchased under the issuer's Employee Stock Purchase Plan."}],"balance_after":47198,"source":{"system":"sec-edgar","filing":"0000899243-22-028248","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000089924322028248/doc4.xml","form_type":"4"}},{"id":363612,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2022-03-21T20:15:55.000Z","date":"2022-03-17","kind":"sale","acquired":false,"shares":34,"price":251.24,"value":8542.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1."}],"balance_after":47356,"source":{"system":"sec-edgar","filing":"0000899243-22-011705","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000089924322011705/doc4.xml","form_type":"4"}},{"id":363611,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2022-03-21T20:15:55.000Z","date":"2022-03-17","kind":"sale","acquired":false,"shares":2799,"price":250.1,"value":700029.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Open market sales reported on this line occurred at a weighted average price of $250.10 (range $250.00 to $250.55)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."}],"balance_after":47390,"source":{"system":"sec-edgar","filing":"0000899243-22-011705","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000089924322011705/doc4.xml","form_type":"4"}},{"id":365008,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2022-02-28T22:27:32.000Z","date":"2022-02-25","kind":"sale","acquired":false,"shares":18,"price":232.8,"value":4190.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Open market sales reported on this line occurred at a weighted average price of $232.80 (range $232.59 to $232.92)."}],"balance_after":50189,"source":{"system":"sec-edgar","filing":"0000899243-22-008123","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000089924322008123/doc4.xml","form_type":"4"}},{"id":365007,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2022-02-28T22:27:32.000Z","date":"2022-02-25","kind":"sale","acquired":false,"shares":87,"price":231.81,"value":20167.47,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Open market sales reported on this line occurred at a weighted average price of $231.81 (range $231.52 to $232.31)."}],"balance_after":50207,"source":{"system":"sec-edgar","filing":"0000899243-22-008123","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000089924322008123/doc4.xml","form_type":"4"}},{"id":365006,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2022-02-28T22:27:32.000Z","date":"2022-02-25","kind":"sale","acquired":false,"shares":115,"price":230.97,"value":26561.55,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Open market sales reported on this line occurred at a weighted average price of $230.97 (range $230.50 to $231.47)."}],"balance_after":50294,"source":{"system":"sec-edgar","filing":"0000899243-22-008123","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000089924322008123/doc4.xml","form_type":"4"}},{"id":365005,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2022-02-28T22:27:32.000Z","date":"2022-02-25","kind":"sale","acquired":false,"shares":77,"price":230.26,"value":17730.02,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Open market sales reported on this line occurred at a weighted average price of $230.26 (range $229.50 to $230.48)."}],"balance_after":50409,"source":{"system":"sec-edgar","filing":"0000899243-22-008123","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000089924322008123/doc4.xml","form_type":"4"}},{"id":365004,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2022-02-28T22:27:32.000Z","date":"2022-02-25","kind":"sale","acquired":false,"shares":28,"price":228.88,"value":6408.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Open market sales reported on this line occurred at a weighted average price of $228.88 (range $228.39 to $229.36)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."}],"balance_after":50486,"source":{"system":"sec-edgar","filing":"0000899243-22-008123","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000089924322008123/doc4.xml","form_type":"4"}},{"id":365003,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2022-02-28T22:27:32.000Z","date":"2022-02-24","kind":"tax_withholding","acquired":false,"shares":2590,"price":227.86,"value":590157.4,"ownership":{"direct":true},"balance_after":50514,"source":{"system":"sec-edgar","filing":"0000899243-22-008123","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000089924322008123/doc4.xml","form_type":"4"}},{"id":365558,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2022-02-22T22:03:40.000Z","date":"2022-02-18","kind":"sale","acquired":false,"shares":120,"price":233.48,"value":28017.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Open market sales reported on this line occurred at a weighted average price of $233.48 (range $233.18 to $233.73)."}],"balance_after":53104,"source":{"system":"sec-edgar","filing":"0000899243-22-007216","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000089924322007216/doc4.xml","form_type":"4"}},{"id":365557,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2022-02-22T22:03:40.000Z","date":"2022-02-18","kind":"sale","acquired":false,"shares":80,"price":232.04,"value":18563.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Open market sales reported on this line occurred at a weighted average price of $232.04 (range $231.89 to $232.13)."}],"balance_after":53224,"source":{"system":"sec-edgar","filing":"0000899243-22-007216","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000089924322007216/doc4.xml","form_type":"4"}},{"id":365556,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2022-02-22T22:03:40.000Z","date":"2022-02-18","kind":"sale","acquired":false,"shares":101,"price":230.42,"value":23272.42,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Open market sales reported on this line occurred at a weighted average price of $230.42 (range $230.05 to $230.75)."}],"balance_after":53304,"source":{"system":"sec-edgar","filing":"0000899243-22-007216","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000089924322007216/doc4.xml","form_type":"4"}},{"id":365555,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2022-02-22T22:03:40.000Z","date":"2022-02-18","kind":"sale","acquired":false,"shares":218,"price":229.52,"value":50035.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Open market sales reported on this line occurred at a weighted average price of $229.52 (range $229.05 to $229.97)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."}],"balance_after":53405,"source":{"system":"sec-edgar","filing":"0000899243-22-007216","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000089924322007216/doc4.xml","form_type":"4"}},{"id":365554,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2022-02-22T22:03:40.000Z","date":"2022-02-17","kind":"tax_withholding","acquired":false,"shares":4114,"price":232.51,"value":956546.14,"ownership":{"direct":true},"balance_after":53623,"source":{"system":"sec-edgar","filing":"0000899243-22-007216","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000089924322007216/doc4.xml","form_type":"4"}},{"id":366083,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2022-02-14T21:22:42.000Z","date":"2022-02-11","kind":"sale","acquired":false,"shares":42,"price":236.85,"value":9947.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Open market sales reported on this line occurred at a weighted average price of $236.85 (range $236.84 to $236.87)."}],"balance_after":57737,"source":{"system":"sec-edgar","filing":"0001209191-22-009249","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000120919122009249/doc4.xml","form_type":"4"}},{"id":366082,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2022-02-14T21:22:42.000Z","date":"2022-02-11","kind":"sale","acquired":false,"shares":70,"price":235.87,"value":16510.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Open market sales reported on this line occurred at a weighted average price of $235.87 (range $235.41 to $236.08)."}],"balance_after":57779,"source":{"system":"sec-edgar","filing":"0001209191-22-009249","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000120919122009249/doc4.xml","form_type":"4"}},{"id":366081,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2022-02-14T21:22:42.000Z","date":"2022-02-11","kind":"sale","acquired":false,"shares":78,"price":234.93,"value":18324.54,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Open market sales reported on this line occurred at a weighted average price of $234.93 (range $234.28 to $235.25)."}],"balance_after":57849,"source":{"system":"sec-edgar","filing":"0001209191-22-009249","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000120919122009249/doc4.xml","form_type":"4"}},{"id":366080,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2022-02-14T21:22:42.000Z","date":"2022-02-11","kind":"sale","acquired":false,"shares":100,"price":233.92,"value":23392.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Open market sales reported on this line occurred at a weighted average price of $233.92 (range $233.26 to $234.24)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."}],"balance_after":57927,"source":{"system":"sec-edgar","filing":"0001209191-22-009249","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000120919122009249/doc4.xml","form_type":"4"}},{"id":366079,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2022-02-14T21:22:42.000Z","date":"2022-02-10","kind":"tax_withholding","acquired":false,"shares":1230,"price":237.74,"value":292420.2,"ownership":{"direct":true},"balance_after":58027,"source":{"system":"sec-edgar","filing":"0001209191-22-009249","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000120919122009249/doc4.xml","form_type":"4"}},{"id":366659,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2022-02-03T21:27:41.000Z","date":"2022-02-01","kind":"grant","acquired":true,"shares":10262,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Restricted stock unit award that vests in installments beginning on 02/24/2023."}],"balance_after":59257,"source":{"system":"sec-edgar","filing":"0001209191-22-006794","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000120919122006794/doc4.xml","form_type":"4"}},{"id":366658,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2022-02-03T21:27:41.000Z","date":"2022-02-01","kind":"grant","acquired":true,"shares":13952,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents earned performance shares with respect to a performance stock unit award granted on 02/03/2021 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2022 and the shares will vest in installments beginning on 02/17/2022."}],"balance_after":48995,"source":{"system":"sec-edgar","filing":"0001209191-22-006794","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000120919122006794/doc4.xml","form_type":"4"}},{"id":366657,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2022-02-03T21:27:41.000Z","date":"2022-02-01","kind":"grant","acquired":true,"shares":3500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents earned performance shares with respect to a performance stock unit award granted on 02/06/2019 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2022 and the shares will vest on 02/24/2022."}],"balance_after":35043,"source":{"system":"sec-edgar","filing":"0001209191-22-006794","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000120919122006794/doc4.xml","form_type":"4"}}],"next_cursor":"2022-02-03T21:27:41.000000Z,366657"}